# Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

> **NCT02716038** · PHASE2 · COMPLETED · sponsor: **Columbia University** · enrollment: 39 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** MPDL3280A
- **DRUG:** Carboplatin
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT02716038
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-07
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2023-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02716038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02716038, "Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02716038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*